Wednesday, August 10, 2022
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Medical Countermeasures

Stockpiling Tamiflu a Waste of Money?

by Global Biodefense Staff
April 14, 2014
Influenza Antiviral Drug

An international team of researchers has found that Tamiflu, the popular influenza antiviral, can shorten symptoms of influenza by half a day, but does not reduce hospital admissions or complications of infection.

The study, published last week in the British Medical Journal (BMJ), shows that Tamiflu modestly reduces the time to first alleviation of symptoms, but can also cause nausea and vomiting and increases the risk of headaches and renal and psychiatric syndromes.

“The trade-off between benefits and harms should be borne in mind when making decisions to use oseltamivir for treatment, prophylaxis, or stockpiling,” concludes the study authors from The Cochrane Collaboration, an independent global healthcare research network.

The data for this most recent review came from data generated by clinical trials that have not previously been open for scrutiny by independent researchers. Efforts by the BMJ and the research team convinced drugmaker Roche, which markets Tamiflu, to release the full data, according to The Scientist.

“There is no credible way these drugs could prevent a pandemic,” Carl Heneghan, one of the lead investigators of the review and a professor at Oxford University, told reporters. “Remember, the idea of a drug is that the benefits should exceed the harms. So if you can’t find any benefits, that accentuates the harms.”

Claims about the effectiveness of such antivirals against complications are key factors in decisions made by governments around the world to stockpile these drugs for seasonal and pandemic influenza surges. The US has reportedly spent more than $1.3 billion buying a strategic reserve of antivirals, while in the UK the government has spent almost £424 million for a stockpile of about 40 million doses.

Read the study at BMJ: Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments.

Tags: AntiviralsInfluenzaPandemicStrategic National Stockpile

Related Posts

Influenza Transmission Spikes During Social Gatherings
Medical Countermeasures

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Adverse Events After Simultaneous COVID-19 mRNA Booster, Flu Vaccination
Medical Countermeasures

Adverse Events After Simultaneous COVID-19 mRNA Booster, Flu Vaccination

July 16, 2022
A Treaty to Break the Pandemic Cycle: Don’t Ignore Key Lessons from the Past Two Years
Policy + Initiatives

A Treaty to Break the Pandemic Cycle: Don’t Ignore Key Lessons from the Past Two Years

July 16, 2022
US Starts Clinical Trial for mRNA Nipah Virus Vaccine
Medical Countermeasures

US Starts Clinical Trial for mRNA Nipah Virus Vaccine

July 11, 2022
Load More

Latest News

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

Bacteria That Causes Melioidosis Confirmed in Environmental Samples in Mississippi Gulf Coast

July 27, 2022
Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

Monkeypox Transmission: Virus Detected in Saliva, Bodily Fluids

July 17, 2022
Influenza Transmission Spikes During Social Gatherings

New Universal Flu Vaccine Offers Broad Protection Against Influenza A Virus Infections

July 17, 2022
Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

Long COVID: National Academies’ Panel Examines Long-Term Health Effects of COVID-19

July 17, 2022

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC